MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
DRIO - DarioHealth Corp
$5.48
-0.33(-5.68%)9:00:00 PM 1/30/2023
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Stock news

    01/24/2023DRIO
    Dario Adds New Senior Vice President of Growth to Expanding Sales Team

    DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the hire of seasoned industry sales leader Matt Alberico as Senior Vice President of Growth to help the Company capitalize on its rapidly growing opportunities across multiple market segments.

    01/9/2023DRIO
    Dario Publishes New Research in Peer Reviewed Journal Demonstrating Improved Outcomes by Race and Ethnicity

    DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the publication of new research in the peer-reviewed journal Applied Sciences demonstrating improved outcomes for users living with diabetes across different racial and ethnic groups. The research appears in the journal as part of the Special Issue: Digital Therapeutics Applications for Chronic Disease Management.

    01/4/2023DRIO
    Institutions profited after DarioHealth Corp.'s (NASDAQ:DRIO) market cap rose US$29m last week butindividual investors profited the most

    A look at the shareholders of DarioHealth Corp. ( NASDAQ:DRIO ) can tell us which group is most powerful. And the group...

    01/3/2023DRIO
    Dario Achieves Goal of 100 Business-to-Business Contracts in 2022

    DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that a large Northeast U.S. supermarket chain (the "Employer") selected Dario to help improve the cardiometabolic health of its employees beginning in the first quarter of 2023, marking the Company reaching 100 enterprise contracts signed. This milestone achievement validates the Company's strategic position as a leading provider of integrated digital chronic con

    12/28/2022DRIO
    DarioHealth Corp. (NASDAQ:DRIO) Q3 2022 Earnings Call Transcript

    DarioHealth Corp. (NASDAQ:DRIO) Q3 2022 Earnings Call Transcript November 15, 2022 DarioHealth Corp. beats earnings expectations. Reported EPS is $-0.64, expectations were $-0.76. Operator: Good day, everyone, and welcome to the DarioHealth Third Quarter 2022 Results Conference Call. Please note, this event is being recorded. I would now like to turn the conference over to […]

    12/22/2022DRIO
    Leading International Wellness Company Selects Dario as Partner for Musculoskeletal Health Improvement Program

    DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a new partnership with ECES, a leading international wellness company, to deploy Dario Move throughout Greece and Cyprus as part of a planned government sponsored initiative. The program will launch in early 2023 with a mandate to screen a minimum of 50,000 citizens in support of improving musculoskeletal health of the Greek and Cyprus populations.

    12/19/2022DRIO
    New Research Published in Peer Reviewed Journal Demonstrating Dario's Musculoskeletal Solution Reduces Back Pain

    DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced the publication of a new study in the peer-reviewed journal Frontiers in Physiology today demonstrating the effectiveness of the Company's musculoskeletal solution, which uses real-time biofeedback and behavior training to reduce back pain.

    12/1/2022DRIO
    Two New Employers Join Dario Through Benefits Brokerage Partner

    DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that two employers selected Dario as part of an offering from a leading benefits brokerage partner that Dario had previously announced (the "Partner"). The employers will deploy Dario's solutions to help improve the cardiometabolic and musculoskeletal health of employees beginning in the first quarter of 2023.

    11/16/2022DRIO
    Dario to Participate in Craig-Hallum and BTIG Digital Health

    DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that management will participate at the following conferences:

    11/14/2022DRIO
    DarioHealth Reports Third Quarter 2022 Financial and Operating Results

    DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today reported financial results for the third quarter 2022 and provided a corporate and B2B (formerly described as B2B2C) update.